A possible role for IVIg in the treatment of soft tissue sarcoma: A clinical case and an experimental model

  • Authors:
    • Ofer Merimsky
    • Isaac Meller
    • Moshe Inbar
    • Sara Bar-Yehuda
    • Yehuda Shoenfeld
    • Pnina Fishman
  • View Affiliations

  • Published online on: April 1, 2002     https://doi.org/10.3892/ijo.20.4.839
  • Pages: 839-843
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

A patient with a malignant peripheral nerve sheath tumor (MPNST) was treated with IVIg for multiple sclerosis. Her MPNST course was remarkably longer and more indolent than expected; she achieved a disease-free interval (DFI) of 30 months. Seven other patients, who were not treated by IVIg, had a relatively aggressive course (median DFI 3 months). These results led us to examine the effect of IVIg on the growth of sarcoma in vitro and in vivo in an experimental model of MCA-bearing mice. When added to MCA-105 sarcoma cell cultures, IVIg produced a dose-dependent inhibitory effect on [3H]-thymidine incorporation. The maximal inhibitory effect was at a concentration of 50 mg/ml IVIg. Cell cycle analysis revealed a hypodiploid peak at the lower fluorescence values which appeared in the samples treated with IVIg. These results demonstrate that the anti-proliferative activity results from an apoptotic effect of IVIg on the tumor cells. In a second set of experiments, we evaluated the capability of IVIg, when administered orally or subcutaneously, to inhibit the growth of MCA-105 sarcoma lung metastases. A decrease in the mean lung weight was observed in the mice that were treated by s.c. or oral administration, the latter being more effective. A possible role for IVIg in the treatment of MPNST and other soft tissue sarcomas is suggested.

Related Articles

Journal Cover

April 2002
Volume 20 Issue 4

Print ISSN: 1019-6439
Online ISSN:1791-2423

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Merimsky O, Meller I, Inbar M, Bar-Yehuda S, Shoenfeld Y and Fishman P: A possible role for IVIg in the treatment of soft tissue sarcoma: A clinical case and an experimental model. Int J Oncol 20: 839-843, 2002.
APA
Merimsky, O., Meller, I., Inbar, M., Bar-Yehuda, S., Shoenfeld, Y., & Fishman, P. (2002). A possible role for IVIg in the treatment of soft tissue sarcoma: A clinical case and an experimental model. International Journal of Oncology, 20, 839-843. https://doi.org/10.3892/ijo.20.4.839
MLA
Merimsky, O., Meller, I., Inbar, M., Bar-Yehuda, S., Shoenfeld, Y., Fishman, P."A possible role for IVIg in the treatment of soft tissue sarcoma: A clinical case and an experimental model". International Journal of Oncology 20.4 (2002): 839-843.
Chicago
Merimsky, O., Meller, I., Inbar, M., Bar-Yehuda, S., Shoenfeld, Y., Fishman, P."A possible role for IVIg in the treatment of soft tissue sarcoma: A clinical case and an experimental model". International Journal of Oncology 20, no. 4 (2002): 839-843. https://doi.org/10.3892/ijo.20.4.839